Observational studyCancer reports (Hoboken, N.J.)2022

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.

Atsushi Hiraoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.